The use of bioisosteric groups in lead optimization

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 4, 2001, Pages 471-478

  Olesen, P H ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Bioisosteres; Bioisosteric replacement; Bioisosteric transformation; Bioisosterism; Lead optimization

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [2 (7 HETEROCYCLOMETHOXYNAPHTHALEN 2 YLMETHOXY)ETHYL]BENZOIC ACID; 4 [2 [7 (4 CYCLOBUTYLTHIAZOL 2 YLMETHOXY)NAPHTHALEN 2YLMETHOXY]ETHYL]BENZOIC ACID; AMPA RECEPTOR ANTAGONIST; CLOZAPINE; COUMARIN DERIVATIVE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EPIBATIDINE; EPIBOXIDINE; LEAD; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; PHENYLETHYLTHIAZOLETHIOUREA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULPIRIDE; THIAZOLE DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; PROTEIN EXPRESSION; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR CONFORMATION; STEREOISOMERISM;

EID: 0034924558     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. In vitro preclinical lead optimization technologies (PLOTs) in pharmaceutical development
2. Bioisosterism: A rational approach in drug design
3. Molecular variations based on isosteric replacements
4. Similarities in bioanalogous structural transformation patterns among various bioactive compound series
5. Isosterism and bioisosterism in drug design
6. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors
7. The role of macromolecular crystallography and structure for drug discovery: Advances and caveats
8. Structural aspects of high affinity ligands for the α4β2 neuronal nicotinic receptor
9. Exo-2-(pyridazin-4-yl)-7-azabicyclo[2.2.1]heptanes: Syntheses and nicotinic acetylcholine receptor agonist activity of potent pyridazine analogues of ±-epibatidine
10. Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors
11. Synthesis and pharmacological evaluation of new 4-[2-(7-heterocycle-methoxynaftalen-2-ylmethoxy)ethyl]benzoic acids as LTD4-antagonists
12. Synthesis and biological activity of new potential antimalarial: 1H-pyrazolo[3,4-b]pyridine derivatives
13. The 2-pyridone antibacterial agents: Bacterial topoisomerase inhibitors
14. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine
15. Thiophene analogs of naphthoxazines and 2-aminotetralins: Bioisosteres with improved relative oral bioavailability, as compared to 5-OH-DPAT
16. Thiazoloindans and thiazolobenzopyrans: A novel class of orally active central dopamine (partial) agonists
17. Synthesis and biological evaluation of 2-(3′-(1 H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (STBPG), a novel mGlu1 receptor antagonist
18. An improved synthesis of 1,2,4-oxadiazoles on solid support
19. Bioisosteres, conformational restriction, and prodrugs: Case history: An example of a conformational restriction approach
20. 1-Aminoisoquinoline as benzamidine isostere in the design and synthesis of orally active thrombin inhibitors
21. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity
22. New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template
23. Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: Synthesis and dopamine receptor binding profiles
24. Conjugated enynes as non-aromatic catechol bioisosteres: Synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype
25. The [(methyloxy)imino]methyl moiety (MOIMM) in the design of a new type of β-adrenergic blocking agent
26. 2,2-Dicyanovinyl as a non-aromatic aryl bioisostere: Synthesis, binding experiments and SAR studies of highly selective dopamine D4 receptor ligands
27. Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere
28. Bioisosteric modification of PETT-HIV-1 RT-inhibitors: Synthesis and biological evaluation
29. Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action
30. Amidinohydrazones as guanidine bioisosteres: Application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors
31. Structural determinants of AMPA agonist activity in analogues of 2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl)propionic acid: Synthesis and pharmacology
32. Investigation of phenolic bioisosterism in opiates: 3-sulfonamido analogues of naltrexone and oxymorphone
33. BIOSTER - A database of structurally analogous compounds